{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:28:45Z","timestamp":1793820525600,"version":"4.6.1"},"reference-count":109,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Non\u2010alcoholic steatohepatitis (NASH) is characterised by hepatic lipid accumulation, cell injury, inflammation and fibrosis. Insulin resistance, a hallmark of type 2 diabetes (T2D) and obesity, is a key pathogenic driver of NASH. Other than difficult\u2010to\u2010maintain lifestyle changes, there are no approved treatments for NASH. Due to their effects on multiple pathophysiological processes, glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) have been tested in disorders related to insulin resistance and metabolic defects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To summarise studies of GLP\u20101RAs relevant to the treatment of NASH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed searches were performed and results were compiled.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Large trials with GLP\u20101RAs in T2D demonstrate highly effective glucose lowering, with body weight loss, and in some cases, reduced cardiovascular events and improved liver transaminases. The GLP\u20101RAs, liraglutide and semaglutide, were associated with clinically relevant, sustained body weight reduction in individuals with overweight or obesity and without T2D. In a phase II trial in NASH, liraglutide reduced metabolic dysfunction, insulin resistance and lipotoxicity in key organs associated with NASH pathogenesis. Furthermore, liraglutide and semaglutide led to histological resolution of NASH in ~40% to 60% of patients, although a statistically significant effect on fibrosis has not been confirmed. Regarding safety, GLP\u20101RAs are associated with gastrointestinal and gallbladder\u2010related adverse events, with the latter perhaps related to weight loss. Meta\u2010analyses do not indicate increased risk of acute pancreatitis, pancreatic cancer or other malignancies with GLP\u20101RAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These studies support the use of GLP\u20101RAs for the improvement of underlying metabolic dysfunction observed in NASH and suggest further long\u2010term phase III trials are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.16794","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T04:59:18Z","timestamp":1646888358000},"page":"944-959","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Review article: role of glucagon\u2010like peptide\u20101 receptor agonists in non\u2010alcoholic steatohepatitis, obesity and diabetes\u2014what hepatologists need to know"],"prefix":"10.1111","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4200-3256","authenticated-orcid":false,"suffix":"4th","given":"A. Sidney","family":"Barritt","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, UNC Liver Center University of North Carolina at Chapel Hill  Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Marshman","sequence":"additional","affiliation":[{"name":"Spirit Medical Communications  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2127-2040","authenticated-orcid":false,"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[{"name":"Department of Medicine Cedars\u2010Sinai Medical Center  Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.052"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1689"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31599"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00960-3"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26717"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15738"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25539"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.049"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.02.003"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.01.023"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00408-y"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116186"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12591"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14255"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.08.038"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066"},{"key":"e_1_2_14_29_1","unstructured":"Byetta\u00aesummary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/byetta\u2010epar\u2010product\u2010information_en.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_30_1","unstructured":"Byetta\u00aeprescribing information. Updated February 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021773s043lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_31_1","unstructured":"Lyxumia\u00aesummary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lyxumia\u2010epar\u2010product\u2010information_en.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_32_1","unstructured":"Adlyxin\u00aeprescribing information. Updated July 2016.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208471Orig1s000lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_33_1","unstructured":"Victoza\u00aesummary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/victoza\u2010epar\u2010product\u2010information_en.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_34_1","unstructured":"Victoza\u00aeprescribing information. Updated November 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022341s036lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_35_1","unstructured":"Bydureon\u00aesummary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/bydureon\u2010epar\u2010product\u2010information_en.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_36_1","unstructured":"Bydureon BCISE\u00aeprescribing information. Updated December 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209210s014lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_37_1","unstructured":"Trulicity\u00aesummary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/trulicity\u2010epar\u2010product\u2010information_en.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_38_1","unstructured":"Trulicity\u00aeprescribing information. Updated February 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125469s033lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_39_1","unstructured":"Ozempic\u00aesummary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ozempic\u2010epar\u2010product\u2010information_en.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_40_1","unstructured":"Ozempic\u00aeprescribing information. Updated January 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209637s003lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00826-0"},{"key":"e_1_2_14_42_1","unstructured":"Rybelsus\u00aesummary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/rybelsus\u2010epar\u2010product\u2010information_en.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_43_1","unstructured":"Rybelsus\u00aeprescribing information. Updated January 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213182s000 213051s001lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14008"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-019-00423-8"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00706-y"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.01.015"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12149"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032759"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13924"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200012120-00015"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15316"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0946-y"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72434"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61375-1"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.52"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_14_69_1","unstructured":"Saxenda\u00aeprescribing information. Updated December 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/206321s012s013s014lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_70_1","unstructured":"Saxenda summary of product characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/saxenda\u2010epar\u2010product\u2010information_en.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_71_1","unstructured":"Wegovy prescribing information. Updated June 2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf. Accessed October 22 2021."},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22794"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302779"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21006"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00476.2011"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23569"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02462.x"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2561"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"e_1_2_14_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12555"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30320"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14065"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108487"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3292"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05265-7"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_2_14_87_1","unstructured":"AlkhouriN HerringJrRW KablerH et al.Safety and efficacy of combination therapies including semaglutide cilofexor and firsocostat in patients with NASH. Presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2020; Abstract LO2."},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16608"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds16-0026"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_14_91_1","unstructured":"Novo NordiskPress release: Gilead Sciences and Novo Nordisk expand NASH clinical collaboration (March 18 2021).https:\/\/www.novonordisk.com\/news\u2010and\u2010media\/news\u2010and\u2010ir\u2010materials\/news\u2010details.html?id=51246. Accessed October 22 2021."},{"key":"e_1_2_14_92_1","unstructured":"ClinicalTrials.gov NCT03987451. Updated July 9 2021.A research study on how semaglutide works in people with fatty liver disease and liver damage.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03987451. Accessed October 22 2021."},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03869.x"},{"key":"e_1_2_14_94_1","doi-asserted-by":"publisher","DOI":"10.3892\/br.2012.18"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23623"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326"},{"key":"e_1_2_14_97_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774"},{"key":"e_1_2_14_98_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.06.047"},{"key":"e_1_2_14_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"e_1_2_14_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04912.x"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2021.07.002"},{"key":"e_1_2_14_102_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146337"},{"key":"e_1_2_14_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-015-0102-8"},{"key":"e_1_2_14_104_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151511"},{"key":"e_1_2_14_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12834"},{"key":"e_1_2_14_106_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0295"},{"key":"e_1_2_14_107_1","unstructured":"ClinicalTrials.gov NCT04976283. Updated September 5 2021.Effect of oral anti\u2010diabetic medication on liver fat in subjects with type II diabetes and non\u2010alcoholic fatty liver.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04976283Accessed October 22 2021."},{"key":"e_1_2_14_108_1","unstructured":"ClinicalTrials.gov NCT04639414. Updated May 26 2021.Combined active treatment in type 2 diabetes with NASH (COMBAT_T2_NASH).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04639414"},{"key":"e_1_2_14_109_1","unstructured":"ClinicalTrials.gov NCT03723252. Updated June 22 2021.Dapagliflozin efficacy and action in NASH (DEAN).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03723252. Accessed October 22 2021."},{"key":"e_1_2_14_110_1","unstructured":"ClinicalTrials.gov NCT04822181. Updated October 21 2021.Research study on whether semaglutide works in people with non\u2010alcoholic steatohepatitis (NASH).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04822181. Accessed October 22 2021."}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.16794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:39:01Z","timestamp":1692722341000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.16794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":109,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/apt.16794"],"URL":"https:\/\/doi.org\/10.1111\/apt.16794","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"2021-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}